Newsletters - July 2000

Newsletters - July 2000

In a recent 20-year study, researchers found that elevated triglycerides, a common type of blood fat in the human body, sharply increase one’s risk of dying from a heart attack, even if the person’s blood cholesterol levels are normal.

This is a landmark study because it is the first of its kind to profile families. Dr. Melissa Austin and coworkers used medical history data collected in the early 1970s from 101 families who had cardiovascular disease and high triglyceride levels. They then traced the health status and cause of death of 685 family members for the next 20 years. The study compared the risk of heart disease death between siblings and offspring versus spouses of individuals with one or two of the common lipid disorders- familial combined hyperlipidemia (FCHL), high triglyceride levels in combination with elevated cholesterol levels in families, and familial hypertrigleridemia (FHTG), elevated triglyceride levels in families. A unique aspect of the study was that most of the family members were relatives of individuals who had a heart attack as well as elevated triglycerides.

The findings of the study are as follows:

  1. Siblings and the offspring of families with FCHL had a 70% higher risk of dying from cardiovascular disease compared to spouses.
  2. A 2-3 fold increased risk of cardiovascular death was predicted in families with FHTG, and it was independent of cholesterol levels.

The life-threatening effects of high triglyceride levels is due to the fact that excess triglycerides can increase the concentrations of 2 types of fat particles, chylomicrons, lipoproteins of the lowest density, and very low density lipoproteins (VLDL). Both contribute to the fatty deposits that obstruct blood flow, increasing one’s risk for a heart attack.

This study has made it evident that knowledge of one’s family history of cardiovascular disease is important because from this information heart attack deaths may be predicted years in advance. To prevent such deaths, levels of both cholesterol and triglycerides should be measured when patients undergo lipid profile testing.

The total number of American families affected by FCHL and FHTG is not known, but Dr. Austin suspects that they probably account for a large number of heart attack deaths nationwide. According to Austin, the next step in preventing and developing treatments for people with cardiovascular disease is to investigate the underlying mechanisms that cause high triglyceride levels to run in families.

Source:
American Heart Association (The 20 year study by M.A. Austin et al. appears in Circulation 2000 Jun 20;101(24), 2777-82.)

Sabinsa Corporation supplies Gugulipid®, Sabinsa’s trademarked standardized extract of the oleogum resin of Commiphora mukul, an Indian medicinal tree that has been shown to reduce serum cholesterol, serum triglycerides, and the detrimental serum lipids while raising the good cholesterol, high density lipoproteins (HDL).

The active ingredients responsible for the use of the plant in the maintenance of healthy cholesterol levels are the guggulsterones, specifically guggulsterone E and guggulsterone Z.

Sabinsa Corporation offers Gugulipid® extract and Gugulipid® 40 Mesh, which are both standardized for a minimum of 2.5% guggulsterones Z & E and Gugulipid® Soft Extract, which is standardized for a minimum of 7.5% guggulsterones Z and E.

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.